Revisiting My PALI-2108 Tissue Penetration Model In Fibrostenotic Crohn's Disease After Phase 1b Readout

Disclosure: The author holds a beneficial long position in Palisade Bio, Inc. (NASDAQ: PALI). This article is provided for informational and educational purposes only and is not financial advice. The reaction-diffusion model discussed here is a speculative theoretical exercise built on estimated parameters and class-level pharmacology, not direct measurements of PALI-0008 in (strictured) human tissue. It cannot reliably predict the outcome of any real-world study. Although the author is a Medical Doctor, this content represents a personal analytical perspective on the company's science and does not constitute medical advice, a diagnosis, or a treatment recommendation. The author receives no compensation for this article and has no business relationship with the company mentioned. Please see the full "Legal Information and Disclosures" section below.

In February I wrote about a speculative reaction-diffusion model I built to explore whether Palisade Bio's PALI-2108 could deliver its active metabolite deep enough into a fibrostenotic bowel wall to reach the tissue layers where fibrosis occurs. PALI-2108 is a prodrug that carries a sugar moiety cleaved by bacterial beta-glucuronidase in the ileocolonic lumen, releasing the active PDE4 inhibitor PALI-0008 at the bowel wall surface while minimizing systemic exposure.

PDE4 enzymes break down cyclic AMP (cAMP), a signaling molecule that suppresses fibrotic pathways including TGF-beta/Smad signaling and myofibroblast activation. By inhibiting PDE4, PALI-0008 raises intracellular cAMP, which is why measuring cAMP in tissue biopsies serves as a direct readout of on-target activity. Earlier systemic PDE4 inhibitors failed on intolerable nausea mediated by PDE4D in the brainstem, which is the core problem the prodrug strategy was designed to solve.

The model divided the bowel wall into six anatomical layers and solved for the balance between diffusion (drug spreading inward from the luminal surface) and vascular clearance (blood flow washing it away). It tested four wall thickness scenarios based on Zhang et al. morphometry of ileal stricture resection specimens, ranging from 2.7 mm in normal ileum to 12 mm in severe strictures. Steady-state penetration reached approximately 3.0 mm in mild and 3.1 mm in moderate fibrostenotic Crohn's disease (FSCD). Under once-daily dosing, the therapeutic front reached roughly two-thirds of that ceiling by Day 14, placing it at approximately 2.1 mm in the moderate scenario (8 mm wall). That depth covers the mucosa, the expanded muscularis mucosae, and the proximal submucosa, one of the two principal fibrotic zones identified by Flier et al. in Crohn's resection specimens. Inflammatory hyperemia was the single most influential variable: doubling vascular clearance nearly halved the penetration depth.

The model suggested that submucosal penetration was physically plausible in early and moderate disease, but the analysis rested on estimated parameters and one critical untested assumption. PALI-2108 depends on bacterial beta-glucuronidase for activation, and the terminal ileum normally harbors far less of that enzyme than the colon. I argued in the original article that small intestinal bacterial overgrowth in the fibrostenotic phenotype (Feng et al., 2024; Klaus et al., 2009), together with cecal reflux near the ileocecal valve, might provide enough enzyme for adequate prodrug conversion. But the Phase 1a data in healthy volunteers and the Phase 1b UC cohort both reported colon tissue pharmacokinetics only. Every penetration estimate in the model was conditional on adequate ileal activation, and no human ileal tissue data had been reported.

On March 30, Palisade Bio reported Phase 1b topline data from the FSCD cohort. Five patients with confirmed ileal stenosis received 14 days of once-daily PALI-2108. Four were on concomitant biologics. Mean disease duration was more than 15 years. There were no serious adverse events and no PDE4 class effects: no nausea, diarrhea, or headache. Two weeks in five patients cannot characterize long-term tolerability, but the absence of class effects is consistent with the prodrug's rationale.

Ileal tissue concentrations exceeded IC90 by Day 14. IC90 is the concentration needed to inhibit 90% of target enzyme activity, and it serves throughout this analysis as the pharmacological threshold. Ileal tissue was approximately three times plasma and colonic tissue approximately five times plasma. Plasma itself exceeded IC90 by the end of titration. Ileal cAMP increased by a mean of 41% with no decrease in any patient, exceeding the 27% colonic cAMP signal from the UC cohort. Fecal calprotectin, a standard marker of intestinal inflammation, fell 59% (268 to 110 µg/g) with a strong inverse correlation to ileal cAMP (r = −0.92). Mean SES-CD dropped from 8.0 to 4.2, a 47.5% reduction, and two of five patients achieved endoscopic remission at two weeks.

Nevertheless, these results come from five uncontrolled patients who were treated over two weeks in a disease with substantial placebo response rates in clinical trials. No improvement can be attributed to drug without a controlled comparison. For context, risankizumab produced Week 12 endoscopic response rates of 29 to 40% in the Phase 3 ADVANCE and MOTIVATE induction trials, and upadacitinib produced 34 to 46% in U-EXCEL and U-EXCEED. Both drugs are now approved for moderate to severe Crohn's disease. The PALI-2108 numbers fall within those ranges at a fraction of the exposure time. What makes the signal harder to dismiss is the convergence across pharmacodynamic, biomarker, and endoscopic endpoints, and the fact that the same pattern appeared independently in the UC cohort, where a separate group of five patients on a different dosing regimen showed the same concordance. Correlated placebo response in one five-patient cohort is plausible. The same pattern appearing twice is less so, though it remains possible.

The observation that matters most for the penetration model is the ileal tissue pharmacokinetics. The terminal ileum is the dominant stricture location in FSCD, involved in roughly 65 to 80% of cases either alone or with concurrent colonic disease (Freeman, 2007). Ileal biopsies above IC90 in every patient tested, with a cAMP increase exceeding the colonic signal, means the prodrug activated at pharmacologically relevant concentrations in the human terminal ileum of FSCD patients. I identified ileal activation as the gating risk in the original analysis, and the data are consistent with that condition being met.

The penetration estimates cannot be tested with available data. Standard biopsies reach approximately 0.6 mm, and there is no way to measure drug concentration throughout the full wall thickness in human patients. The model was never intended to predict exact tissue penetration. It was a pharmacokinetic bridging exercise: if the drug cannot physically reach the fibrotic zone, it cannot work in FSCD regardless of its mechanism. The question was whether penetration to the submucosa was at least plausible.

There is one clinical observation from the Phase 1b that touches on this question. During the webcast, a question around minute 45:30 asked how close the enrolled patients were to surgery. Management answered that at least one patient's impassable stricture became passable after 14 days. Passability depends on luminal diameter across the full wall thickness. If the drug affected only the superficial mucosa, explaining a meaningful diameter change in established stenosis would be difficult. But two weeks is far too short for collagen remodeling. Type I collagen has a half-life on the order of one to two months, and the anti-fibrotic drugs pirfenidone and nintedanib required 52-week trials to demonstrate functional stabilization in idiopathic pulmonary fibrosis (Richeldi et al., 2014; King et al., 2014). The most likely explanation for improved passability at two weeks is resolution of inflammatory edema. This still implies penetration beyond the mucosa, since I very much doubt that mucosal edema alone can cause impassable strictures. Edema reduction and anti-fibrotic activity are not mutually exclusive: the former could restore passability in weeks while the latter, if the drug reaches the submucosa, could slow further collagen deposition over months.

The press release reported plasma drug concentrations above IC90 by the end of titration. This likely refers to the active metabolite PALI-0008, not the prodrug: PALI-2108 is designed not to be absorbed intact, and any PALI-0008 detected in plasma was released locally in the gut and then absorbed into the bloodstream. The tissue-to-plasma ratios (approximately 3x ileum, 5x colon) confirm that drug concentrations are highest at the gut wall and decrease toward the systemic circulation, consistent with local release followed by partial systemic absorption. My model assumed negligible blood concentrations. If the free plasma fraction is near IC90, vascular supply could in principle deliver therapeutic concentrations to deeper bowel wall layers from the serosal side, extending the penetration range beyond what luminal diffusion alone achieves. But "above IC90" in the press release likely refers to total drug (bound plus free), and the free fraction that diffuses into tissue could be substantially lower. Without knowing the plasma protein binding of PALI-0008, the degree to which vascular supply supplements luminal penetration remains an open question.

The case that PALI-2108 could work as an anti-fibrotic in FSCD rests on a chain of conditional probabilities. The prodrug must activate in the ileum: observed in all five Phase 1b patients. The drug must penetrate to the fibrotic zone: the model suggests this is plausible in early and moderate disease, and the data are consistent but cannot verify it. PDE4 inhibition must suppress fibrotic signaling in the gut wall: supported by class-level biology and nerandomilast precedent in pulmonary fibrosis, but unproven for this drug in human intestinal tissue. The patient must be treated early enough that the wall has not thickened beyond what luminal delivery can reach, though the plasma observation raises the possibility that vascular supply extends this range.

Phase 1b strengthened the first link in this chain. We still do not know whether PALI-0008 is an effective anti-fibrotic drug in the gut. Phase 2 at 12 weeks should begin to lift the fog.

Follow me on X for frequent updates (@chaotropy).

Legal Information and Disclosures

General Disclaimer & No Financial Advice: The content of this article is for informational and educational purposes only. It represents the personal opinions of the author as of the date of publication and may change without notice. The author is not a registered investment advisor or financial analyst. This content is not intended to be, and shall not be construed as, financial, legal, tax, or investment advice. It does not constitute a personal recommendation or an assessment of suitability for any specific investor. This article does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. Readers should conduct their own independent due diligence and consult with a certified financial professional before making any investment decisions. This article is not a securities research report and has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Medical Disclaimer: Although the author possesses a medical background, the information presented here regarding medical technologies, clinical trials, or pharmaceutical mechanisms is strictly for the purpose of educational discussion and general commentary regarding the underlying science. It does not constitute medical advice, a diagnosis, or a treatment recommendation, nor does it establish a physician-patient relationship. Readers should never disregard professional medical advice or delay in seeking it because of something read on this website. Always consult a qualified healthcare provider regarding any medical condition.

Computational Model Disclaimer: The reaction-diffusion model presented in this article is a speculative theoretical exercise. It relies on estimated parameters, published morphometric data from resection specimens, and class-level pharmacological assumptions rather than direct measurements of PALI-0008 diffusivity, binding, or clearance in (strictured) human tissue. Many inputs (including tissue binding ratios, vascular clearance rates, layer-specific diffusivities, and the degree of inflammatory hyperemia) are approximated from literature on related compounds or inferred indirectly. The simulation code has not been independently audited, peer-reviewed, or verified by a third party. Bugs in the implementation could alter results materially. The model’s outputs should be understood as order-of-magnitude estimates illustrating relative trends, not as quantitative predictions of drug penetration in any individual patient or clinical trial. Reproducing the model’s numerical outputs does not constitute independent validation of its assumptions or conclusions.

Accuracy and Third-Party Data: Clinical trial data, press releases, regulatory filings, and published literature referenced in this article are sourced from ClinicalTrials.gov, company press releases, peer-reviewed journals, and conference abstracts. While the author believes these sources to be reliable, the completeness, timeliness, or correctness of this data cannot be guaranteed. The author assumes no liability for errors, omissions, or the results obtained from the use of this information.

Disclosure of Interest: The author holds a beneficial long position in Palisade Bio, Inc. (NASDAQ: PALI). The author reserves the right to buy or sell these securities at any time without further notice. The author receives no direct compensation for the production of this content and maintains no business relationship with the company. The author has no access to non-public trial data, unblinded interim results, or internal company information. Readers should be aware that the author’s financial interest in the company creates a potential for confirmation bias in model design and interpretation, despite efforts to mitigate this through systematic sensitivity analysis and the inclusion of conservative assumptions. Confirmation bias can manifest in subtle ways, including the choice of parameter ranges, the structural assumptions of the model, and the framing of results. Independent replication of the model with alternative assumptions is encouraged.

Forward-Looking Statements & Risk: This article contains forward-looking statements regarding regulatory outcomes (such as FDA decisions), clinical results, and market potential. These statements are predictions based on current expectations and are subject to significant risks and uncertainties. Actual results may differ materially. Investing in biotechnology and pharmaceutical securities involves a high degree of risk, including the potential for total loss of principal. Past performance is not indicative of future results. No reader should rely on this article as a basis for any investment decision. The author has no obligation to update this article if new information becomes available or if the author’s position changes. This content is not directed at or intended for distribution to any person or entity in any jurisdiction where such distribution would be contrary to law or regulation.

Copyright: All original content, including text and images, is the property of the author and may not be copied, reproduced, or published, in whole or in part, without the author's prior written consent, except as permitted by applicable law or the terms of the platform on which it is published. Use of this content for training machine learning or AI models is not permitted without explicit authorization. Third-party or public domain images remain subject to their respective rights and are not claimed as the author's property.